May. 16 at 11:13 PM
$SPRO there is no buy out coming. I expect a "buzzer beater" deal from
$GSK to acquire tebi rights ahead of FDA approval like they did on an out-license with AlfaSigma in March 2026 for a non-core drug lynavoy. GSK received
$300MLN upfront,
$100MLN on FDA approval and ongoing royalties from Alfa. The deal was signed about 2 weeks before FDA approved lynavoy.
Read the tea leaves: there will be a buyout of the remaining Tebi rights SPRO owns, crystallizing the value upfront on agreed upon NPV analysis (i.e., add up all royalties + milestones less SPRO royalties owed to Meiji) with anticipated growth in Tebi re
$2.7bln + peak sales out to 2041 & discounted back to PV.
Anyone hoping for a buyout of SPRO equity will be disappointed.
My hope is market is caught off guard by the news, we get a power gap to
$10+ zone depending on tebi valuation and squeeze higher due to 13k call options losing delta hedge & excitement on reverse merger target causing rush of buying.
Have a game plan.
